Left Bundle Branch Block Clinical Trial
Official title:
Correlation of Clinical Outcomes With ECG Findings in Patients With Left Bundle Branch Block Being Evaluated for Acute Coronary Syndrome - a Prospective Cohort Study
Verified date | August 2015 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Purpose of the study:
The goal of this study is to evaluate the relationship of electrocardiogram (ECG) findings
with clinical outcomes in a cohort of patients with left bundle branch block (LBBB) who are
being evaluated for acute coronary syndrome (ACS) in the Emergency Department (ED).
Background and significance:
The significance of specific ECG findings in patients with LBBB being evaluated for ACS has
been inadequately studied, and this gap in knowledge is a barrier to optimal management of
this population. Due to the speed, availability, low cost, and non-invasive nature of the
ECG, it would be ideal to identify ECG characteristics that help to risk stratify these
patients in order to inform clinical decision-making, reduce unnecessary invasive testing,
and conserve resources.
Methods:
In this prospective observational study the investigators will identify a consecutive series
of adult patients with LBBB presenting to the ED with suspicion of ACS. The investigators
will collect data including demographics, cardiac risk factors, initial ECG measurements,
lab and radiographic results, procedure results, and clinical outcomes such as 30-day death
or myocardial infarction (MI). The investigators will analyze the data using a cohort study
design to calculate odds ratios between ECG characteristics and the outcomes of interest.
Status | Terminated |
Enrollment | 8 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 and older - LBBB on ECG - Presenting to the ED and being evaluated for ACS Exclusion Criteria: - Prisoners - Institutionalized individuals - Patients who are incapable of giving legally effective consent - Patients who cannot understand spoken English |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Duke University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit | Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED. |
The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome. | No |
Primary | Specificity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit | Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED. |
The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome. | No |
Primary | Positive likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit | Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED. |
The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome. | No |
Primary | Negative likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit | Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED. |
The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome. | No |
Secondary | Sensitivity of various exploratory ECG findings for positive cardiac biomarkers | Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research. | The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED. | No |
Secondary | Specificity of various exploratory ECG findings for positive cardiac biomarkers | Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research. | The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED. | No |
Secondary | Positive likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers | Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research. | The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED. | No |
Secondary | Negative likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers | Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research. | The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02537782 -
Myocardial Work and Metabolism in CRT
|
N/A | |
Suspended |
NCT04701112 -
Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure
|
N/A | |
Completed |
NCT01694550 -
QT Interval in Patients With Pacemaker Dependency
|
N/A | |
Completed |
NCT01129635 -
Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging
|
N/A | |
Recruiting |
NCT02659137 -
HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients
|
N/A | |
Terminated |
NCT01872234 -
MADIT ASIA Cardiac Resynchronization Trial
|
Phase 3 | |
Terminated |
NCT01735916 -
MIRACLE EF Clinical Study
|
N/A | |
Completed |
NCT01922544 -
EP-Catheter Guided CS-Lead Implantation
|
N/A | |
Terminated |
NCT01325480 -
High Septal Pacing for Cardiac Resynchronization Therapy
|
Phase 0 | |
Completed |
NCT02543281 -
Adaptive CRT Effect on Electrical Dyssynchrony
|
N/A |